Bristol-myers Squibb Compnay

George N Karageorge

John E Macor

Katherine S Takaki

Brett T Watson

Guanglin Luo

Gene Michael Dubowchik

Prasad V Chaturvedula

Graham S Poindexter

George O Tora

Michael Frederick Parker

Andrew P Degnan

Ling Chen

Xiaojun Han

Rita Civiello

Daniel J Keavy

Xiang Jun J Jiang

Richard Eric Olson

Joanne J Bronson

Joseph P Yevich

Carolyn Diane Dzierba

Ramkumar Rajamani

Dalton King

Bireshwar Dasgupta

Christiana I Iwuagwu

James R Epperson

Shikha Vig

Karen L Leboulluec

Charles Mark Conway

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Pyrrolotriazine kinase inhibitors

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. 

Selective NR2B antagonists

The present invention relates to methods of treating neurogenic vasodilation, neurogenic inflammaton, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors using pharmaceutical compositions comprising compounds of Formula (I) 

Anti-migraine treatments

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

Calcitonin gene related peptide receptor antagonists

Novel substituted fluorene compunds of Formula I are active as melatonergic agents: ##STR1## wherein: X=H, halogen, OH or OZ;

Ethylamido fluorenes and improved method of making same

New melatonergic agents are phenyl alkanyl or phenyl alkyl substituted carboxamides and ureas of Formula I: ##STR1## wherein: R.sub.1 =C.sub.1-3 alkyl, allyl, C.sub.3-6 cycloalkyl substituted C.sub.1-4 alkyl;

Melatonergic agents

Growing community of inventors

Portland, CT, United States of America

George N Karageorge